Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a report released on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.09) per share for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals' Q2 2025 earnings at ($0.09) EPS and Q3 2025 earnings at ($0.10) EPS.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The firm had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%.
Several other analysts also recently commented on LXRX. Leerink Partnrs lowered Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Piper Sandler decreased their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. StockNews.com started coverage on shares of Lexicon Pharmaceuticals in a report on Wednesday. They set a "sell" rating on the stock. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $1.00 price objective (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $3.67.
Read Our Latest Report on LXRX
Lexicon Pharmaceuticals Stock Up 2.7 %
Shares of Lexicon Pharmaceuticals stock traded up $0.01 during trading on Monday, reaching $0.37. 4,971,496 shares of the company traded hands, compared to its average volume of 3,979,048. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The firm has a market capitalization of $90.25 million, a PE ratio of -0.49 and a beta of 1.04. The company has a 50 day moving average price of $0.70 and a 200-day moving average price of $1.10. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.62.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of LXRX. BNP Paribas Financial Markets lifted its holdings in Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 13,246 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Lexicon Pharmaceuticals by 2.1% during the fourth quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 15,249 shares during the period. Arizona State Retirement System grew its stake in shares of Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 16,136 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after purchasing an additional 24,615 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Lexicon Pharmaceuticals by 27.4% during the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock valued at $101,000 after purchasing an additional 29,319 shares in the last quarter. Institutional investors own 74.70% of the company's stock.
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Further Reading
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
